BOCOM INTL (03329) releases interim results, with shareholders' net loss of HK$283 million, a year-on-year decrease of 20.47%.

26/08/2025

CICC (03329) released its interim performance for the six months ended on June 30, 2025, including earnings and other income.

BOCOM INTL (03329) announced its interim results for the six months ended June 30, 2025, with total revenue and other income of HKD 276 million, a decrease of 3.11% year-on-year. Shareholders' loss attributable to owners of the company was HKD 283 million, narrowing by 20.47% year-on-year. Loss per share was HKD 0.1.

AUSTAR (06118) released its interim performance results, with a net profit attributable to shareholders of 24.99 million yuan, an increase of 325.37% year-on-year.

I-CABLE COMM (01097) announces interim performance with a net loss of approximately HK$217 million, a year-on-year decrease of 14.95%.

Shanghai Fosun Pharmaceutical(02196): The drug registration application for Injection of Chlorhexidine Hydrochloride was accepted by the National Medical Products Administration.

AUSTAR (06118) released its interim performance results, with a net profit attributable to shareholders of 24.99 million yuan, an increase of 325.37% year-on-year.

I-CABLE COMM (01097) announces interim performance with a net loss of approximately HK$217 million, a year-on-year decrease of 14.95%.

Shanghai Fosun Pharmaceutical(02196): The drug registration application for Injection of Chlorhexidine Hydrochloride was accepted by the National Medical Products Administration.